Search Results
Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020
Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020
Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer
Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy
Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer
Dr. Brufsky on Multiparametric Genomic Assays in Breast Cancer
An Overview of Immunotherapy in Breast Cancer - An Interview with Adam Brufsky
Interview with Dr. Adam Brufsky
CDK4/6 Inhibitors in Metastatic Disease
R/R HER2+ mBC: Interpreting Findings From the NALA Trial
Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer
What Changes Monday Morning? | Practice Applications in Breast Cancer | Metastatic Disease